Peter Sander

Summary

Affiliation: University of Zurich
Country: Switzerland

Publications

  1. ncbi Fitness cost of chromosomal drug resistance-conferring mutations
    Peter Sander
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, CH 8028 Zurich, Switzerland
    Antimicrob Agents Chemother 46:1204-11. 2002
  2. ncbi A recA deletion mutant of Mycobacterium bovis BCG confers protection equivalent to that of wild-type BCG but shows increased genetic stability
    Peter Sander
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8028, Zurich, Switzerland
    Vaccine 21:4124-7. 2003
  3. ncbi Lipoprotein processing is required for virulence of Mycobacterium tuberculosis
    P Sander
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8028 Zurich, Schweiz
    Mol Microbiol 52:1543-52. 2004
  4. ncbi LspA inactivation in Mycobacterium tuberculosis results in attenuation without affecting phagosome maturation arrest
    Silvana K Rampini
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 32, CH 8006 Zurich, Switzerland
    Microbiology 154:2991-3001. 2008
  5. ncbi A mycobacterial smc null mutant is proficient in DNA repair and long-term survival
    Carolin Güthlein
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, 8006 Zurich, Switzerland
    J Bacteriol 190:452-6. 2008
  6. ncbi Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens
    Pål Johansen
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Clin Vaccine Immunol 18:907-13. 2011
  7. ncbi Characterization of the mycobacterial NER system reveals novel functions of the uvrD1 helicase
    Carolin Güthlein
    Institut fur Medizinische Mikrobiologie, University of Zurich, Gloriastrasse 30 32, CH 8006, Zurich, Switzerland
    J Bacteriol 191:555-62. 2009
  8. ncbi Engineering the rRNA decoding site of eukaryotic cytosolic ribosomes in bacteria
    Sven N Hobbie
    Institut fur Medizinische Mikrobiologie, Universität Zürich and Laboratorium für Organische Chemie, ETH Zurich, Switzerland
    Nucleic Acids Res 35:6086-93. 2007
  9. ncbi Tuberculosis vaccine strain Mycobacterium bovis BCG Russia is a natural recA mutant
    Peter M Keller
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8006 Zurich, Switzerland
    BMC Microbiol 8:120. 2008
  10. ncbi Deletion of dop in Mycobacterium smegmatis abolishes pupylation of protein substrates in vivo
    Frank Imkamp
    ETH Zurich, Institute of Molecular Biology and Biophysics, Zurich, Switzerland
    Mol Microbiol 75:744-54. 2010

Collaborators

Detail Information

Publications25

  1. ncbi Fitness cost of chromosomal drug resistance-conferring mutations
    Peter Sander
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, CH 8028 Zurich, Switzerland
    Antimicrob Agents Chemother 46:1204-11. 2002
    ..These results argue against expectations that link decreased levels of antibiotic consumption with the decline in the level of resistance...
  2. ncbi A recA deletion mutant of Mycobacterium bovis BCG confers protection equivalent to that of wild-type BCG but shows increased genetic stability
    Peter Sander
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8028, Zurich, Switzerland
    Vaccine 21:4124-7. 2003
    ..The availability of a genetically stable, fully immunogenic BCG is important for the future development of BCG as a live vaccine...
  3. ncbi Lipoprotein processing is required for virulence of Mycobacterium tuberculosis
    P Sander
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8028 Zurich, Schweiz
    Mol Microbiol 52:1543-52. 2004
    ..In addition, these results hint at a promising new target for therapeutic intervention, as a highly specific inhibitor of bacterial lipoprotein signal peptidases is available...
  4. ncbi LspA inactivation in Mycobacterium tuberculosis results in attenuation without affecting phagosome maturation arrest
    Silvana K Rampini
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 32, CH 8006 Zurich, Switzerland
    Microbiology 154:2991-3001. 2008
    ..These observations demonstrate severe attenuation even in the presence of arrested phagosome maturation, and point to a role for the early phagosome in growth restriction of the M. tuberculosis lspA mutant...
  5. ncbi A mycobacterial smc null mutant is proficient in DNA repair and long-term survival
    Carolin Güthlein
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, 8006 Zurich, Switzerland
    J Bacteriol 190:452-6. 2008
    ..Surprisingly, inactivation of smc did not result in recognizable phenotypes in hallmark assays characteristic for the function of these genes. This is in contrast to data for smc null mutants in other species...
  6. ncbi Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens
    Pål Johansen
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Clin Vaccine Immunol 18:907-13. 2011
    ..In conclusion, our results suggest that phagosome maturation and lysosomal delivery of BCG facilitate mycobacterial antigen presentation and enhance immunogenicity...
  7. ncbi Characterization of the mycobacterial NER system reveals novel functions of the uvrD1 helicase
    Carolin Güthlein
    Institut fur Medizinische Mikrobiologie, University of Zurich, Gloriastrasse 30 32, CH 8006, Zurich, Switzerland
    J Bacteriol 191:555-62. 2009
    ..This implies that in mycobacteria (which lack the postreplicative mismatch repair system) NER, and particularly the UvrD1 helicase, is involved in the processing of a subset of recombination-associated mismatches...
  8. ncbi Engineering the rRNA decoding site of eukaryotic cytosolic ribosomes in bacteria
    Sven N Hobbie
    Institut fur Medizinische Mikrobiologie, Universität Zürich and Laboratorium für Organische Chemie, ETH Zurich, Switzerland
    Nucleic Acids Res 35:6086-93. 2007
    ..The activities of the hybrid ribosomes indicate that helix 44 of the rRNA decoding site behaves as an autonomous domain, which can be exchanged between ribosomes of different phylogenetic domains for study of function...
  9. ncbi Tuberculosis vaccine strain Mycobacterium bovis BCG Russia is a natural recA mutant
    Peter M Keller
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8006 Zurich, Switzerland
    BMC Microbiol 8:120. 2008
    ..All vaccine substrains in use stem from one source, strain Bacille Calmette-Guérin. However, they differ in regions of genomic deletions, antigen expression levels, immunogenicity, and protective efficacy...
  10. ncbi Deletion of dop in Mycobacterium smegmatis abolishes pupylation of protein substrates in vivo
    Frank Imkamp
    ETH Zurich, Institute of Molecular Biology and Biophysics, Zurich, Switzerland
    Mol Microbiol 75:744-54. 2010
    ..Furthermore, we demonstrate that a putative N-terminal ATP-binding motif is crucial for catalysis, as a single point mutation (E10A) in this motif abolishes Dop activity both in vivo and in vitro...
  11. ncbi Identification of apolipoprotein N-acyltransferase (Lnt) in mycobacteria
    Andreas Tschumi
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8006 Zurich, Switzerland
    J Biol Chem 284:27146-56. 2009
    ..In M. smegmatis and M. tuberculosis the open reading frames are annotated as MSMEG_3860 and M. tuberculosis ppm1, respectively...
  12. ncbi Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis
    Thomas Grau
    Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
    Antimicrob Agents Chemother 56:1142-5. 2012
    ....
  13. ncbi Lipoprotein synthesis in mycobacteria
    Mandana Rezwan
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 32, CH 8006 Zurich, Switzerland
    Microbiology 153:652-8. 2007
    ..M. tuberculosis, the causative agent of tuberculosis, is one of the most devastating pathogens in the world. This article reviews recent findings on the synthesis, localization and function of lipoproteins in mycobacteria...
  14. ncbi A ?-Lactamase Based Reporter System for ESX Dependent Protein Translocation in Mycobacteria
    Tobias Rosenberger
    Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
    PLoS ONE 7:e35453. 2012
    ..Thus we have developed a powerful tool to dissect the molecular mechanisms of ESX dependent protein translocation and to screen for novel components of the ESX systems on a large scale...
  15. ncbi Binding of neomycin-class aminoglycoside antibiotics to mutant ribosomes with alterations in the A site of 16S rRNA
    Sven N Hobbie
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastr 30 32, CH 8006 Zurich, Switzerland
    Antimicrob Agents Chemother 50:1489-96. 2006
    ..U1495 wobble base pair to the Watson-Crick interaction pair 1406C-1495G yields ribosomal drug susceptibilities to 4,5-aminoglycosides comparable to those seen with the wild-type A site...
  16. ncbi Breaking down the wall: fractionation of mycobacteria
    Mandana Rezwan
    Institut fur Medizinische Mikrobiologie, Gloriastrasse 32, Universität Zürich CH 8006 Zürich, Switzerland
    J Microbiol Methods 68:32-9. 2007
    ..The protocol of subcellular fractionation was then validated for pathogenic species by applying the method to Mycobacterium bovis BCG cells, an attenuated strain of the M. tuberculosis complex...
  17. ncbi Characterization of a Mycobacterium tuberculosis mutant deficient in pH-sensing adenylate cyclase Rv1264
    Dorothea Dittrich
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8006 Zurich, Switzerland
    Int J Med Microbiol 296:563-6. 2006
    ..Consequently Rv1264 has been suggested to sense the phagosomal milieu resulting in adaption of M. tuberculosis to its intracellular niche. A targeted knock-out mutant deficient in Rv1264, however, exhibits wild-type virulence...
  18. ncbi Involvement of CD252 (CD134L) and IL-2 in the expression of cytotoxic proteins in bacterial- or viral-activated human T cells
    Michael Walch
    Division of Cell Biology, Institute of Anatomy, University of Zurich, Zurich, Switzerland
    J Immunol 182:7569-79. 2009
    ..These data indicate a distinct CTL effector function in response to intracellular pathogens triggered via differing endogenous IL-2 production upon costimulation through CD252...
  19. ncbi DNA damage induction of recA in Mycobacterium tuberculosis independently of RecA and LexA
    Elaine O Davis
    Division of Mycobacterial Research, National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK
    Mol Microbiol 46:791-800. 2002
    ..These observations demonstrate convincingly for the first time that there is a novel mechanism of DNA damage induction in M. tuberculosis that is independent of LexA and RecA...
  20. ncbi The majority of inducible DNA repair genes in Mycobacterium tuberculosis are induced independently of RecA
    Lucinda Rand
    National Institute for Biomedical Research, London, UK
    Mol Microbiol 50:1031-42. 2003
    ..Amongst these are genes involved in nucleotide excision repair, base excision repair, damage reversal and recombination. Thus, it appears that this novel mechanism of gene regulation is important for DNA repair in M. tuberculosis...
  21. ncbi The functions of OmpATb, a pore-forming protein of Mycobacterium tuberculosis
    Catherine Raynaud
    The Division of Mycobacterial Research, The National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK
    Mol Microbiol 46:191-201. 2002
    ..The involvement with pH is likely to contribute to the ability of M. tuberculosis to overcome host defence mechanisms and grow in a mammalian host...
  22. ncbi A synthetic mammalian gene circuit reveals antituberculosis compounds
    Wilfried Weber
    Department of Biosystems Science and Engineering, Eidgenossische Technische Hochschule Zurich, Mattenstrasse 26, CH 4058 Basel, Switzerland
    Proc Natl Acad Sci U S A 105:9994-8. 2008
    ..The discovery of antituberculosis compounds by using synthetic mammalian gene circuits may establish a new line of defense against multidrug-resistant M. tuberculosis...
  23. ncbi Mycobacterium tuberculosis prevents inflammasome activation
    Sharon S Master
    Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
    Cell Host Microbe 3:224-32. 2008
    ..Thus, we uncovered a previously masked role for IL-1beta in the control of Mtb and a mycobacterial system that prevents inflammasome and, therefore, IL-1beta activation...
  24. ncbi Interaction of Rv1625c, a mycobacterial class IIIa adenylyl cyclase, with a mammalian congener
    Ying Lan Guo
    Abt Pharmazeutische Biochemie, Pharmazeutisches Institut, Universitat Tubingen, Morgenstelle 8, D 72076 Tubingen, Germany
    Mol Microbiol 57:667-77. 2005
    ..In vitro growth characteristics and in vivo organ infection and mortality were unaltered in the knockout strain indicating that AC Rv1625c alone is not a virulence factor...
  25. ncbi Lack of mismatch correction facilitates genome evolution in mycobacteria
    Burkhard Springer
    , , Gloriastrasse 30/32, , Switzerland
    Mol Microbiol 53:1601-9. 2004
    ..Together, the lack of mismatch correction and a high stringency of initiation of homologous recombination provide an adequate strategy for mycobacterial genome evolution, which occurs by gene duplication and divergent evolution...